Your Biotech GTM Launch Does Not Have a Marketing Problem. It Has a Handoff Problem.
The finger-pointing starts predictably. Sales says marketing generates leads that go nowhere. Marketing says sales ignores every lead they send over. Leadership calls it a culture problem and schedules a team offsite. Six months later, nothing has changed because the offsite addressed the symptom, not the cause.
The actual problem is structural. It lives in your CRM, your lead routing logic, and the absence of a shared definition for what a qualified opportunity even looks like. Before your next GTM launch, fix the architecture. The culture will follow.
Why Alignment Keeps Failing at Growth-Stage Biotechs
Growth-stage biotech companies move fast by necessity. Commercial teams get stood up quickly, often with a CRM that was configured by whoever had admin access at the time, a marketing automation platform connected loosely to that CRM, and handoff processes that live in someone’s head or a shared doc that is already out of date.
The result is a shadow CRM situation: the data in the system does not reflect what is actually happening in the field. Marketing measures MQLs by their own definition. Sales measures pipeline by their own definition. Neither team can see what happens to a lead after it crosses the line from one function to the other. When you cannot trace a lead from first touch to closed deal inside a single source of truth, you are not running a GTM process. You are running two separate processes that occasionally intersect, and hoping the intersection produces revenue.
This matters even more in life sciences, where launch windows are narrow, market access timelines are unforgiving, and the cost of a misaligned commercial quarter is not just a missed number. It can affect fundraising narratives, partnership conversations, and investor confidence in the team’s ability to execute.
The Three Things RevOps Actually Needs to Fix Before Launch
Most GTM alignment frameworks focus on communication cadences or shared KPIs. Those things matter, but they are downstream of three foundational decisions that RevOps owns:
1. Define the pipeline together, in writing, before launch. Marketing-to-sales funnel alignment starts with a shared funnel definition. That means sitting in a room with marketing leadership, sales leadership, and RevOps and answering these questions explicitly: What makes a lead an MQL? What converts an MQL to an SQL? What triggers a sales-accepted lead, and who owns that status change? What does “qualified opportunity” mean in your specific commercial model?
In biotech, this often gets complicated by the sales motion. You may be selling to a research director, a procurement team, and a medical or scientific affairs function simultaneously. Your funnel stages need to reflect that reality, not a generic B2B SaaS template. Build the definitions into the CRM as enforceable fields and picklists, not just a shared doc. Lead status governance is not a bureaucratic exercise. It is the infrastructure your forecast confidence depends on.
2. Design the handoff as a workflow, not a conversation. A handoff that depends on a human remembering to do something will fail at scale. Design the marketing-to-sales handoff as an automated workflow with SLAs attached to each step. When a lead hits MQL status, what happens in the next four hours? Who gets notified? What data fields need to be populated for the lead to be actionable by the rep? If those fields are empty, does the lead go back to marketing enrichment automatically?
This is RevOps workflow audit territory. Map the current state of your handoff process, identify every step that requires manual intervention or assumption, and replace it with a system-enforced trigger. Your CRM can handle most of this if it is configured intentionally. What you are building is pipeline governance: a set of rules that ensure every lead moves through the funnel in a predictable, traceable way that both teams can see in real time.
3. Build a single source of truth before the first lead enters the funnel. The worst time to reconcile two different views of pipeline is in your monthly revenue review when a launch is underway. The second-worst time is the week before launch. The right time is eight to twelve weeks before any commercial activity starts.
That means your CRM is the authoritative record for every lead, contact, account, and opportunity. Your marketing automation platform writes to it. Your sales engagement tool writes to it. If a rep takes a note on a call, it lives in the CRM. Revenue intelligence dashboards pull from one place, and every report that goes to leadership reflects the same numbers that sales and marketing see in their own views.
Account-level revenue visibility is not a reporting feature. It is the precondition for every strategic conversation you will have during a launch. Without it, you are having those conversations with incomplete information, and the decisions you make will reflect that.
The Life Sciences Layer You Cannot Ignore
Biotech and pharma commercial teams operate under constraints that generic RevOps playbooks do not account for. Depending on your product and the stage of launch, you may have regulatory requirements around how and where you capture customer interaction data. Medical, legal, and regulatory review processes affect the content marketing puts in front of prospects, which means the handoff between marketing content approval and sales enablement is itself a compliance workflow, not just a content workflow.
Resource constraints are also real. A growth-stage biotech with a ten-person commercial team cannot staff a dedicated RevOps function the way a scaled enterprise can. That is a legitimate constraint, and it means the systems and workflows you build before launch need to be simple enough to maintain with limited bandwidth. GTM alignment for biotech and medtech is not about building the most sophisticated stack. It is about building the right stack for your current scale, with clear paths to expand as the team grows.
What to Do Before Your Next Launch
If you are preparing for a commercial launch or running a mid-cycle GTM reset, start with a pipeline audit for life sciences before you brief the marketing team on campaign strategy or push the sales team on outreach cadences. Audit what lives in your CRM today. Map your current handoff process and identify every gap between what the system says and what actually happens. Define your funnel stages with both teams in the room. Then build the workflows that make those definitions real.
That sequence matters. Culture follows infrastructure. When marketing can see that their MQLs are being worked, they invest more in quality. When sales can see exactly what marketing is sending them and why, they trust the process. Alignment is not a feeling. It is the output of a system that both teams can rely on.
At Vida Solutions, we work with growth-stage life sciences companies to build that system before launch, or rebuild it when a GTM reset is overdue. If you are stepping into a launch without clean pipeline definitions and a governed handoff process, it is worth a conversation before the first qualified lead falls through a gap in the architecture.